Study aims and goal: Phase IIb, randomized, double-blind, placebo-controlled study in parallel groups assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington’s Disease with choreic movements.
No. of study participants and sites: This Phase IIb study aims to recruit participants from 22 sites in France, Germany, Italy, Poland, Spain, Switzerland and the UK.
For further information see the clinical trial registration.